Ticker League

Net Income for Regeneron Pharmaceuticals (REGN)

Latest filings through · Reported

Metric

TTM

$4.42B

YoY change

+2.1%

5Y CAGR

+5.1%

Peak year (2021)

$8.08B

Net Income history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: $4.50B

Net Income growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: +2.1%

Net Income history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

  • 2025$4.50B+2.1%
  • 2024$4.41B+11.6%
  • 2023$3.95B-8.9%
  • 2022$4.34B-46.3%
  • 2021$8.08B+129.9%
  • 2020$3.51B+66.0%
  • 2019$2.12B-13.4%
  • 2018$2.44B+104.0%
  • 2017$1.20B+33.8%
  • 2016$895.52M+40.8%
  • 2015$636.06M+82.7%
  • 2014$348.07M-18.0%
  • 2013$424.36M-43.4%
  • 2012$750.27M-438.3%
  • 2011−$221.76M+112.3%
  • 2010−$104.47M+54.0%
  • 2009−$67.83M-18.0%
  • 2008−$82.71M-21.7%
  • 2007−$105.60M+3.2%
  • 2006−$102.34M+7.2%
  • 2005−$95.45M-328.9%
  • 2004$41.70M-138.8%
  • 2003−$107.46M-13.6%
  • 2002−$124.38M+63.3%
  • 2001−$76.18M+228.1%
  • 2000−$23.21M+0.5%
  • 1999−$23.10M+168.6%
  • 1998−$8.60M-25.9%
  • 1997−$11.60M-64.2%
  • 1996−$32.40M+37.9%
  • 1995−$23.50M-23.5%
  • 1994−$30.70M-23.1%
  • 1993−$39.90M+108.9%
  • 1992−$19.10M+324.4%
  • 1991−$4.50M+36.4%
  • 1990−$3.30M—

Net Income values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Net Income at Regeneron Pharmaceuticals (REGN)

According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $4.42B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

In 2025, Regeneron Pharmaceuticals (REGN) net income totalled $4.50B – edged up 2.1% year-over-year.

Regeneron Pharmaceuticals net income compound annual growth for the 2020–2025 (5 years) window is +5.1%, sustaining 2 straight years of year-over-year growth.

Regeneron Pharmaceuticals net income peaked at $8.08B in 2021; the latest annual figure is $4.50B in 2025 (44.2% below peak).

The record annual net income stands at $8.08B, reached in 2021; the historical low of −$221.76M was recorded in 2011.

Regeneron Pharmaceuticals Net Income by Year

Regeneron Pharmaceuticals Net Income 2025: $4.50B

2025's net income for Regeneron Pharmaceuticals came in at $4.50B, edged up 2.1% from 2024.

Regeneron Pharmaceuticals Net Income 2024: $4.41B

Regeneron Pharmaceuticals posted net income of $4.41B in 2024, grew 11.6% from 2023.

Regeneron Pharmaceuticals Net Income 2023: $3.95B

In 2023, Regeneron Pharmaceuticals reported net income of $3.95B, declined 8.9% below 2022.

Regeneron Pharmaceuticals Net Income 2022: $4.34B

Regeneron Pharmaceuticals net income in 2022 was $4.34B, plunged 46.3% below 2021.

Regeneron Pharmaceuticals Net Income 2021: $8.08B

Regeneron Pharmaceuticals net income in 2021 was $8.08B.

See more financial history for Regeneron Pharmaceuticals (REGN).

Sector peers by Net Income

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest net income

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation